Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 64   

Articles published

ARRY 3.48 -0.09 (-2.52%)
price chart
Array BioPharma To Present At The Morgan Stanley 2014 Global Healthcare ...
3, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, -5.80% today announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley 2014 Global Healthcare Conference in New York City.
Related articles »  
Climbing NASDAQ Stocks: Endocyte, Inc.(NASDAQ:ECYT), Array Biopharma Inc ...
The stock has traded within a range of $3.39 to $6.66 over the past 52 weeks. Array Biopharma Inc(NASDAQ:ARRY) currently has a bid price of $3.60 x 3,000 and an offer price of $4.18 x 500.
Related articles »  
Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer
11, 2014 /PRNewswire/ -- Array BioPharma Inc. ARRY, -5.80% a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced the appointment of ...
Related articles »  
Rising Pharmaceutical Companies: Array BioPharma Inc(NASDAQ:ARRY ...
Array BioPharma Inc(NASDAQ:ARRY) gained eleven cents to move to a new closing price of $3.75, a 3.02% increase in value from the previous closing price.
Related articles »  
Biotech Losers To Watch: Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Array ...
Array BioPharma Inc. (NASDAQ:ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, on 11 September announced the appointment of Victor ...
Related articles »  
Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes ...
Array BioPharma Inc.'s stock finished Friday's session 0.79% lower at $3.76. A total of 2.82 million shares were traded, which was above its three months average volume of 1.48 million shares.
Related articles »  
Phase 2 binimetinib data presented at ESMO
Investigator Reinhard Dummer, M.D., presented final results from a 117-patient Phase 2 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, a patient population with an especially poor prognosis.
Phase 2 Trial Of Binimetinib In NRAS Melanoma Shows Promising Clinical Activity  CNNMoney
Related articles »  
Hot News: FreeSeas Inc. (NASDAQ:FREE), Array BioPharma (NASDAQ:ARRY ...
On 11 September Array BioPharma, Inc. (NASDAQ:ARRY) announced the appointment of Victor Sandor, M.D., as Chief Medical Officer.
Active Stock's Momentum: Glimcher Realty Trust (GRT), Array Biopharma Inc ...
Array Biopharma Inc (NASDAQ:ARRY) unveiled that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley 2014 Global Healthcare Conference in New York City.
Watch List - Anacor Pharmaceuticals Inc (NASDAQ:ANAC), Array Biopharma Inc ...
Las Vegas, NV - September 22, 2014 - (TechSonian) - Anacor Pharmaceuticals Inc (NASDAQ:ANAC) recently declared its financial results for the quarter ended June 30, 2014.
Related articles »